Tidutamab manufacturers
- Tidutamab
-
- $297.00
-
2026-07-27
- CAS:2148354-90-7
- Purity: 97.9% (SDS-PAGE); 97.8% (SEC-HPLC)
- Supply Ability: 10g
|
| | Tidutamab Basic information |
| Product Name: | Tidutamab | | Synonyms: | Tidutamab;Research Grade Tidutamab (DHD91601);Research Grade Tidutamab | | CAS: | 2148354-90-7 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tidutamab Structure]() |
| | Tidutamab Chemical Properties |
| | Tidutamab Usage And Synthesis |
| Uses | Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC)[1]. | | in vivo | Tidutamab (XmAb-18087; 3 mg/kg; i.p.; single dose) stimulates human T cell killing of SSTR2+ A549 lung carcinoma tumors in NSG mice[1]. | Animal Model: | NSG mice[1] | | Dosage: | 3 mg/kg | | Administration: | Intraperitoneal injection; single dose | | Result: | lnduced anti-tumor activity in human PBMC-engrafted NSG mice. |
| | References | [1] Hyung LS, et, al. Anti-SSTR2 × anti-CD3 bispecific antibody induces potent killing of human tumor cellsin vitroand in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors. Cancer Res(2017) 77 (13_Supplement): 3633. |
| | Tidutamab Preparation Products And Raw materials |
|